# A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T

> **NCT05468190** · PHASE1 · UNKNOWN · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 48 (estimated)

## Conditions studied

- Metastatic Tumor
- Advanced Solid Tumor
- Renal Cell Carcinoma
- Ovarian Cancer
- Cervix Cancer

## Interventions

- **BIOLOGICAL:** CD70 CAR-T cells
- **BIOLOGICAL:** CD70 CAR-T cells

## Key facts

- **NCT ID:** NCT05468190
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-17
- **Primary completion:** 2024-07-17
- **Final completion:** 2025-07-17
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2023-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05468190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05468190, "A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05468190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*